Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDI Study of Methadone/Buprenorphine with DCV/ASV/Beclabuvir
NCT02045693Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Feb 2014
- Primary completion
- Apr 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of daclatasvir, asunaprevir and beclabuvir in hepatitis C (HCV) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Maximum observed concentration of R-Methadone at Day 13, Area under the concentration-time curve in one dosing interval of R-Methadone at Day 13 and 2 more. Started Feb 2014; status: completed.
02
Drugs
daclatasvirasunaprevirbeclabuvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02045693.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02045693.